Table 5 Stability studies of optimized Pulsincap
From: Optimizing pulsatile release of febuxostat for managing gout flares: a chronotherapeutic approach
Time (weeks) | Before | After | ||
|---|---|---|---|---|
% CDR at 1 h | % CDR at 8 h | % CDR at 1 h | % CDR at 8 h | |
1 | 100 ± 0.002% IR | 22.66 ± 0.015% SR | 100 ± 0.001% IR | 22.13 ± 0.023% SR |
2 | 100 ± 0.003% IR | 21.76 ± 0.01% SR | ||
3 | 100 ± 0.001% IR | 22.02 ± 0.076% SR | ||
4 | 100 ± 0.001% IR | 21.98 ± 0.045% SR | ||